BioCentury
ARTICLE | Clinical News

Zebinix regulatory update

March 29, 2017 12:56 AM UTC

EMA’s CHMP recommended a label expansion for Zebinix eslicarbazepine acetate from Bial-Portela to include its use as monotherapy to treat partial-onset seizures, with or without secondary generalizati...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Bial-portela & Ca. S.A.